Risk · ReputationalJun 20, 2026 · 06:50 CET
Novartis shuts down two neurology drug programmes
Novartis confirmed this morning that it is winding down two flagship neurodegenerative-disease programmes to refocus on oncology. Stock −2.4% pre-market. Directly conflicts with the Schneider family's stated purpose (funding neurology research for their daughter).
3 of 3 selected
Hubertus & Carmen Schneider
UHNWI · Zug, CH · CET
Position5.8%
CHF exposureCHF 0.58M
Channel Phone
StyleValues-driven
Draft, tailored to client DNA
Sends via Phone at next sensible window for CET.
Eugen & Lisa Räber
UHNWI · Zurich, CH · CET
Position4.2%
CHF exposureCHF 0.42M
Channel Phone
StyleRisk-sensitive
Draft, tailored to client DNA
Sends via Phone at next sensible window for CET.
Karin Stadler
HNWI · Bern, CH · CET
Position5.0%
CHF exposureCHF 0.90M
Channel Email
StyleNumbers-first
Draft, tailored to client DNA
Sends via Email at next sensible window for CET.
Every message requires RM approval before send. No automated trades are placed from this screen.